AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30444283
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment for 4 weeks
Trial: 30444686
Drug: Two cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycles of chemotherapy
Trial: 30444686
Drug: Eight cycles
RxNorm normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight cycles of chemotherapy
Trial: 30444686
Drug: Pre-emptive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-emptive chemotherapy for infants younger than 2 months with hepatomegaly
Trial: 30446007
Drug: AZD9150 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9150 at 2 mg/kg
Trial: 30446007
Drug: AZD9150 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9150 at 3 mg/kg
Trial: 30446007
Drug: AZD9150 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9150 (both doses)
Trial: 30446575
Drug: Treatment according
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment according to the 2015 ACR guideline
Trial: 30446741
Drug: Low-dose anti-thymocyte
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose anti-thymocyte globulin (ATG) 5 mg/kg and low-dose posttransplant cyclophosphamide (PTCy) 50 mg/kg
Trial: 30446785
Drug: BEZ235 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEZ235 1000 mg qd
Trial: 30446785
Drug: BEZ235 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEZ235 1200 mg qd
Trial: 30446785
Drug: BEZ235 1400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEZ235 1400 mg qd
Trial: 30446785
Drug: BEZ235 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEZ235 (both dosing schedules)
Trial: 30447969
Drug: Conventional MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional MRI - abnormal signal in the posterior limb of internal capsule (PLIC)
Trial: 30448343
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy with FLOT in combination with surgical resection of the primary tumour and metastases
Trial: 30449033
Drug: Endoscopic ultrasound-guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic ultrasound-guided injection of cyanoacrylate (CYA) and a less-expensive coil
Trial: 30450591
Drug: Aurora B
RxNorm normalized name: BENZALKONIUM CHLORIDE 1.3 mg in 1 mL TOPICAL LIQUID [AURORA BODY WASH CRISP WATERS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aurora B kinase inhibitor BI 811283 in combination with cytarabine
Trial: 30451655
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) 50 mg once weekly for 24 weeks
Trial: 30452500
Drug: ROP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROP treatment at 32 weeks' postmenstrual age
Trial: 30452500
Drug: ROP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROP treatment at 33 weeks' postmenstrual age
Trial: 30452666
Drug: VSV-EBOV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VSV-EBOV vaccine (single-dose regimen)
Trial: 30455171
Drug: Tablet-based app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet-based app for consent process
Trial: 30456327
Drug: Daily Isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily Isoniazid with peer counseling
Trial: 30460518
Drug: Apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5 mg bid (octogenarians)
Trial: 30460518
Drug: Apixaban 2.5
RxNorm normalized name: apixaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 2.5 mg bid (octogenarians with appropriately reduced dose)
Trial: 30460684
Drug: Ixazomib 4
RxNorm normalized name: ixazomib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib 4 mg and cyclophosphamide 300 mg/m² with low-dose dexamethasone
Trial: 30461442
Drug: Nonmedical prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonmedical prescription stimulants (NPS) (days of NPS use)
Trial: 30461441
Drug: Participants' perceptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants' perceptions about drug use behaviors among US adults
Trial: 30462243
Drug: Diuretic-induced hyponatremia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic-induced hyponatremia
Trial: 30462688
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) patients
Trial: 30466205
Drug: Bright Light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright Light Therapy (BLT) administered in the morning for 10 weeks with dose escalation at 7.5, 10, 15, 30, and 45 minutes/day.
Trial: 30466205
Drug: Bright Light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright Light Therapy (BLT) administered at mid-day for 10 weeks with dose escalation at 7.5, 10, 15, 30, and 45 minutes/day.
Trial: 30466410
Drug: Crizotinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib (250 mg twice/day)
Trial: 30467013
Drug: Tacrolimus (TAC)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (TAC) therapy initiated, monitored for biliary concentrations during the first 7 days.
Trial: 30467135
Drug: Fesoterodine, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine, administered over a treatment phase of 12 weeks (three cycles of 4 weeks each).
Trial: 30467135
Drug: Standardised questionnaires
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised questionnaires (AD symptoms and quality of life) and bladder and bowel diaries at the end of each treatment cycle.
Trial: 30467809
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL methoxyflurane (self-administered via inhalation under supervision)
Trial: 30467809
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care (SoC) including IV morphine for severe pain (NRS ≥ 7); IV paracetamol or ketoprofen for moderate pain (NRS 4-6)
Trial: 30467809
Drug: Healthcare professional-rated
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthcare professional-rated practicality of study treatment at 30 min after randomisation using a 5-point Likert scale
Trial: 30468243
Drug: PI3K-targeted drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI3K-targeted drugs
Trial: 30470569
Drug: Direct-acting antiviral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antiviral drugs for chronic hepatitis C
Trial: 30471345
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg ICG
Trial: 30471345
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg ICG
Trial: 30471345
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg ICG
Trial: 30471345
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg ICG
Trial: 30471345
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg ICG
Trial: 30471555
Drug: Nutraceutical combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical combination (NC) containing red yeast rice and berberine
Trial: 30471652
Drug: Ixazomib-cyclophosphamide-dexamethasone (ICd)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib-cyclophosphamide-dexamethasone (ICd) followed by ixazomib maintenance; 4.0 mg of ixazomib, 300 mg (Arm A) or 400 mg (Arm B)
Trial: 30472553
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (cholecalciferol) 100,000 IU bolus dose followed by 20,000 IU per week
Trial: 30472651
Drug: ld-IL2 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ld-IL2 (1 million IU/day for 5 days, followed by fortnightly injections for 6 months)
Trial: 30472660
Drug: Continuous EEG
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous EEG monitoring with antiepileptic drugs (AEDs)
Trial: 30472660
Drug: Continuous EEG
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous EEG monitoring without antiepileptic drugs (AEDs)
Trial: 30473706
Drug: Pressurized intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin/doxorubicin or oxaliplatin
Trial: 30475950
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years
Trial: 30476179
Drug: 17β-estradiol transdermal
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17β-estradiol transdermal patch (PATCH)
Trial: 30476968
Drug: Cetuximab (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (500 mg/m2) plus irinotecan (180 mg/m2) biweekly
Trial: 30477436
Drug: Cognitive function
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive function assessed by the Montreal Cognitive Assessment, Trail making A and B, ten-word immediate and delayed recall test, Controlled Oral Word Association, Global Deterioration Scale, Ascertain Dementia 8 item informant questionnaire.
Trial: 30477455
Drug: PBI-4050 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBI-4050 at a total daily oral dose of 800 mg for an initial 24 weeks with continuation for an additional 36 or 48 weeks
Trial: 30477513
Drug: Preparation from
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation from scratch
Trial: 30477513
Drug: Food preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food preparation behaviors
Trial: 30477544
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg IM ketamine
Trial: 30477544
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg IM midazolam and 5 mg IM haloperidol
Trial: 30478168
Drug: Intravenous colistimethate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous colistimethate sodium (CMS) with a loading dose of 9 million international units (MU) followed by a maintenance dose of 3 MU every 8 hours.
Trial: 30478190
Drug: Vorolanib (X-82)
RxNorm normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorolanib (X-82) 400 mg once daily (q.d.)
Trial: 30478190
Drug: Vorolanib (X-82)
RxNorm normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorolanib (X-82) 20-800 mg (various dosing regimens)
Trial: 30480082
Drug: Resveratrol, glucose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol, glucose, and malate (RGM) - 15 mL per dose (5 g dextrose, 5 g malate, 5 mg resveratrol) twice a day for 1 year
Trial: 30480082
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - matching placebo ingested with an 8 oz glass of commercial unsweetened grape juice twice a day for 1 year
Trial: 30480323
Drug: Tocilizumab administered
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab administered by intravenous infusion (dosage regimen not specified)
Trial: 30480323
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or intravenous glucocorticoid therapy
Trial: 30480489
Drug: Reduced Dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced Dose CT (RD)
Trial: 30480489
Drug: Standard Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Dose CT (SD)
Trial: 30485854
Drug: Nalmefene 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 18 mg taken as needed with psychosocial interventions
Trial: 30486767
Drug: Total cell-free
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total cell-free DNA levels above the median (9800 alleles/mL)
Trial: 30486767
Drug: Total cell-free
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total cell-free DNA levels below the median (9800 alleles/mL)
Trial: 30487142
Drug: Concurrent measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent measurement of CRP
Trial: 30487998
Drug: GP2015 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP2015 (50 mg subcutaneously, once weekly for 24 weeks)
Trial: 30487998
Drug: ETN (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETN (50 mg subcutaneously, once weekly for 24 weeks)
Trial: 30488179
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (5 g/m2) individualized dosing using a fixed algorithm with 0-2 rate adjustments based on methotrexate levels during infusion
Trial: 30488420
Drug: Immunoglobulin G-degrading
RxNorm normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS)
Trial: 30497397
Drug: Triage system
RxNorm normalized name: Triage First Aid Station KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triage system (Rapid Emergency Triage and Treatment System - RETTS)
Trial: 30497431
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) with 10 Gy directed to the involved mediastinum/hilar stations and/or positive surgical margins, followed by adjuvant systemic therapy.
Trial: 30497431
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) with 30 Gy to the primary tumor for the unresectable patient.
Trial: 30498390
Drug: SBI 5
RxNorm normalized name: Somatostatin Analog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBI 5 g BID for 3 weeks
Trial: 30498564
Drug: Pioglitazone 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 0.25 mg/kg once daily
Trial: 30498564
Drug: Pioglitazone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 0.5 mg/kg once daily
Trial: 30498564
Drug: Pioglitazone 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 0.75 mg/kg once daily
Trial: 30499605
Drug: Dabigatran (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (standard dose)
Trial: 30499605
Drug: Dabigatran (reduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (reduced dose)
Trial: 30499605
Drug: Rivaroxaban (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (standard dose)
Trial: 30499605
Drug: Rivaroxaban (reduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (reduced dose)
Trial: 30499734
Drug: 10% intravenous
RxNorm normalized name: glucose 10% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% intravenous immunoglobulin (IVIG; Flebogamma) administered at 1 g/kg over two consecutive days
Trial: 30501550
Drug: Hydroxyurea (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (15 to 20 mg/kg/day for 6 months, followed by dose escalation)
Trial: 30501869
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hyper-CVAD and ponatinib (45 mg per day for the first 14 days of cycle 1, then reduced to 30 mg per day at cycle 2, and further to 15 mg once a complete molecular response was achieved)
Trial: 30501869
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hyper-CVAD and ponatinib (maintenance with ponatinib daily at 30 mg or 15 mg, vincristine 2 mg intravenously on day 1, and prednisone 200 mg orally on days 1-5 monthly for 2 years)
Trial: 30501870
Drug: Bortezomib (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1.3 mg/m²) with lenalidomide and dexamethasone (VRd) plus panobinostat (10 mg)
Trial: 30501870
Drug: Bortezomib (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1.3 mg/m²) with lenalidomide and dexamethasone (VRd) plus panobinostat (15 mg)
Trial: 30501916
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake in normal weight children (859.0 ± 195.9 mg)
Trial: 30506110
Drug: Intravenous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous trastuzumab (H IV) treatment
Trial: 30506283
Drug: Personalized PRRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized PRRT (adjusted injected activity to deliver a prescribed absorbed dose to the kidney)
Trial: 30506309
Drug: Daily home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily home spirometry and accelerometry during the peri-diagnostic period
Trial: 30506309
Drug: Daily home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily home spirometry and accelerometry
Trial: 30506533
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (2 cycles of CapeOX or 3 cycles of mFOLFOX6) followed by elective surgery
Trial: 30506533
Drug: Elective surgery
RxNorm normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective surgery without neoadjuvant chemotherapy
Trial: 30508189
Drug: bDMARD monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bDMARD monotherapy
Trial: 30508189
Drug: MTX monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX monotherapy and bDMARDs
Trial: 30508620
Drug: Inverse-planned, multibeam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inverse-planned, multibeam intensity modulated radiation therapy (IMRT)
Trial: 30509296
Drug: Successful cfDNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful cfDNA assay without heparin
Trial: 30509296
Drug: Heparin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (in vitro experiments)
Trial: 31118759
Drug: Pregabalin, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin, dosage and duration not specified
Trial: 30511200
Drug: TAS-114 combined
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-114 combined with S-1, administered orally under fasting conditions at doses ranging from 5-240 mg/m
Trial: 30511337
Drug: Response to
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response to percutaneous coronary intervention, platelets, sex hormones, and myocardial damage at baseline
Trial: 30513489
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for HD participants, 16 weekly sessions.
Trial: 30517727
Drug: Hazelnuts (∼57
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hazelnuts (∼57 g/d) for 16 weeks
Trial: 30518443
Drug: Thrombolysis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolysis treatment group (110 patients)
Trial: 30518443
Drug: Non-thrombolysis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-thrombolysis treatment group (94 patients)
Trial: 30518502
Drug: Axicabtagene ciloleucel
RxNorm normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axicabtagene ciloleucel (target dose of 2 × 10^5 cells) administered on day 0
Trial: 30519877
Drug: Life support-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life support-based comprehensive treatment regimen including mechanical life support, immunological modulation with glucocorticoids and immunoglobulin, and antiviral reagents (neuraminidase inhibitor)
Trial: 30520001
Drug: Bupropion XL
RxNorm normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion XL 150 mg once daily for 5 days, then 300 mg once daily from days 6 to 14
Trial: 30522700
Drug: Pembrolizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (10 mg/kg every 2 weeks for ≤24 months)
Trial: 30522992
Drug: Usual psychopharmacological
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual psychopharmacological therapy plus the Social-Local-Mobile app